PRAME like-6 Inhibitors
PRAME-like-6 inhibitors pertain to a chemical class designed to interact with the PRAME-like-6 protein, a member of the PReferentially expressed Antigen in MElanoma (PRAME) family of proteins, which is known for its role in various biological processes. These inhibitors are typically small molecules that can selectively bind to the active or allosteric sites of the PRAME-like-6 protein, often resulting in the modulation of its activity. The precise mechanism of action of these inhibitors depends on the structure of the PRAME-like-6 protein, which is characterized by specific domains that allow for the interaction with other molecules and possibly the regulation of its function in the cell.
The design of PRAME-like-6 inhibitors is a sophisticated process that requires an in-depth understanding of the molecular architecture of the target protein. Researchers often utilize techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy to elucidate the three-dimensional structure of the protein, which then informs the development of inhibitors that are complementary in shape and chemical properties to the target site. Such inhibitors typically exhibit high specificity, aiming to bind to PRAME-like-6 with minimal interaction with other proteins to reduce off-target effects. The development of PRAME-like-6 inhibitors also involves a process of optimization, where the chemical structure of initial hit compounds is modified to improve their binding affinity, selectivity, and overall physicochemical properties, such as solubility and stability. This process is iterative and can involve the synthesis of numerous analogs to identify the most effective compounds within the class.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By inhibiting EGFR, it can downregulate signaling pathways that may be involved in the activation and stabilization of PRAME like-6, leading to its functional suppression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By altering chromatin structure and gene expression, it can modulate the expression of genes that indirectly control the levels and activity of PRAME like-6. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). It disrupts PI3K/Akt signaling, which can indirectly influence the stability and function of PRAME like-6. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that blocks the MAPK/ERK pathway. This inhibition can reduce the transcriptional activity of genes that are potentially involved in regulating PRAME like-6 expression or function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress mTORC1 signaling. This action can lead to reduced protein synthesis and indirectly decrease the levels of proteins like PRAME like-6. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. This process can modulate protein turnover and potentially decrease the stability of PRAME like-6. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor with targets including RAF, VEGFR, and PDGFR. By inhibiting these kinases, it can attenuate signaling pathways that either stabilize or activate PRAME like-6. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 is an MDM2 antagonist that activates p53. Activated p53 can induce cell cycle arrest and apoptosis, leading to a decrease in the levels of proteins such as PRAME like-6. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor aimed at BCR-ABL, c-Kit, and PDGFR. By blocking these kinases, it might indirectly lead to downregulation of pathways that positively affect PRAME like-6 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. This broad action can lead to a shutdown of various signaling pathways that are essential for the activation of PRAME like-6. | ||||||